Skip to main content

Withdrawn Drugs

By

These is much ongoing work within the drug discovery and toxicology communities to better understand the safety aspects of approved drugs and clinical candidate compounds, and for this reason there is clear interest in why some drugs have been approved but then subsequently withdrawn from the market. This post describes the information for withdrawn drugs that is currently available in ChEMBL. 

Within ChEMBL (release 24) there are 192 drugs that have been annotated as approved but then subsequently withdrawn from the market for one or more reasons.  For each of these drugs, the year of withdrawal, region of withdrawal and reason for withdrawal (‘withdrawn_reason’) have been available since release 22 of ChEMBL (see ftp://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_22/archived/chembl_22_release_notes.txt), while the classification of the reason for withdrawal (‘withdrawn_class’)  is a new feature for ChEMBL (release 24).  The withdrawn information is available for relevant drugs on the Compound Report Card of the web interface, or within the molecule_dictionary sql table. 

For example Rosiglitazone, an anti-diabetes medicine, was withdrawn from the EU in 2011 due to the increased risk of ischaemic heart disease (http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp ). Note that Rosiglitazone has been withdrawn from the EU market, but is still available within other regions of the world and hence the Compound Report Card shows that the drug is ‘approved’ (see information within the top of the Compound Report Card - https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL121), while the detail about the region of withdrawal shows that it has been withdrawn from the EU (further down the Compound Report Card). ‘Cardiotoxicity’ is annotated as the withdrawn_class for Rosiglitazone.



Using the withdrawn classification (‘withdrawn_class’), similar withdrawn drugs can be grouped together. For example, if you are interested in approved drugs that have been withdrawn for ‘hepatoxicity’, ‘cardiotoxicity’, ‘neurotoxicity’ etc then you can now easily group drugs withdrawn for similar reasons. Therefore the pie chart displayed below shows 45 drugs that have been withdrawn for hepatotoxicity reasons. 

Of the annotated classes of withdrawn drugs, 37 drugs have more than one reason for withdrawal from the markets (and therefore are assigned more than one class of withdrawn reason on the pie chart); 9 of the withdrawn drugs have not been assigned a withdrawn_class because they have a non-specific reason (e.g. 'Multi-Organ Toxicities') that cannot be given a withdrawn_class without further investigation of the underlying literature; and 44 of the withdrawn drugs do not currently have a reason described in ChEMBL. 

Further work is planned to annotate additional withdrawn drug information. 
This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116030. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.



Comments

Post a Comment

Popular posts from this blog

ChEMBL 34 is out!

By
We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.
Post a Comment
Read more

New SureChEMBL announcement

By
(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f
Post a Comment
Read more

Accessing SureChEMBL data in bulk

By
It is the peak of the summer (at least in this hemisphere) and many of our readers/users will be on holiday, perhaps on an island enjoying the sea. Luckily, for the rest of us there is still the 'sea' of SureChEMBL data that awaits to be enjoyed and explored for hidden 'treasures' (let me know if I pushed this analogy too far). See here and  here for a reminder of SureChEMBL is and what it does.  This wealth of (big) data can be accessed via the SureChEMBL interface , where users can submit quite sophisticated and granular queries by combining: i) Lucene fields against full-text and bibliographic metadata and ii) advanced structure query features against the annotated compound corpus. Examples of such queries will be the topic of a future post. Once the search results are back, users can browse through and export the chemistry from the patent(s) of interest. In addition to this functionality, we've been receiving user requests for  local (behind the
Post a Comment
Read more

New Drug Approvals - Pt. XVII - Telavancin (Vibativ)

By jpo
The latest new drug approval, on 11th September 2009 was Telavancin - which was approved for the treatment of adults with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria , including Staphylococcus aureus , both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains. Telavancin is also active against Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus anginosus group (includes S. anginosus, S. intermedius and S. constellatus ) and Enterococcus faecalis (vancomycin susceptible isolates only). Telavancin is a semisynthetic derivative of Vancomycin. Vancomycin itself is a natural product drug, isolated originally from soil samples in Borneo, and is produced by controlled fermentation of Amycolatopsis orientalis - a member of the Actinobacteria . Telavancin has a dual mechanism of action, firstly it inhibits bacterial cell wall synthesis by interfering with the polymerization and cross-linking of peptid
Post a Comment
Read more

A python client for accessing ChEMBL web services

By
Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d
1 comment
Read more